OptimizeRx Corp. (NASDAQ:OPRX) Receives Average Rating of "Moderate Buy" from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $11.8125.

Several research firms have recently commented on OPRX. Stifel Nicolaus increased their price objective on OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a report on Friday, August 8th. Zacks Research upgraded OptimizeRx from a "hold" rating to a "strong-buy" rating in a research note on Friday, September 5th. JMP Securities increased their price target on OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a research note on Monday, August 11th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a research note on Friday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of OptimizeRx in a research note on Saturday, September 27th.

Insiders Place Their Bets

In other OptimizeRx news, Director Patrick D. Spangler sold 11,120 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $17.49, for a total transaction of $194,488.80. Following the transaction, the director owned 44,215 shares in the company, valued at $773,320.35. This trade represents a 20.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.60% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Manatuck Hill Partners LLC increased its position in OptimizeRx by 139.5% during the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company's stock worth $6,142,000 after buying an additional 265,000 shares during the period. Massar Capital Management LP bought a new position in OptimizeRx during the 2nd quarter worth $297,000. BNP Paribas Financial Markets increased its position in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock worth $55,000 after buying an additional 2,215 shares during the period. Balyasny Asset Management L.P. bought a new position in shares of OptimizeRx in the second quarter worth $2,111,000. Finally, Ameriprise Financial Inc. bought a new position in shares of OptimizeRx in the second quarter worth $943,000. Institutional investors own 76.47% of the company's stock.

OptimizeRx Trading Up 6.5%

NASDAQ OPRX opened at $18.75 on Friday. The company has a market cap of $348.19 million, a PE ratio of -34.72 and a beta of 1.25. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $20.69. The stock has a 50 day moving average of $16.95 and a 200-day moving average of $13.20.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.